Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration
Prudence A Francis
The Breast | CHURCHILL LIVINGSTONE | Published : 2019
Updated results from the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT) have helped to identify differential value of various adjuvant endocrine therapy strategies in high-risk and low-risk premenopausal early breast cancer. With a median follow-up of 8 years in SOFT, there is now a significant improvement in disease-free survival (DFS) for those assigned to receive 5 years of tamoxifen plus ovarian function suppression (T + OFS) as compared with tamoxifen (T). Further improvement in DFS was observed for those assigned exemestane plus OFS (E + OFS). While the relative treatment effect from the addition of OFS to tamoxifen in the no chemotherapy and pri..View full abstract
Awarded by National Health & Medical Research Council Australia
The SOFT and TEXT trials were conducted by the International Breast Cancer Study Group (IBCSG) in collaboration with the Breast International Group (BIG) cooperative groups, and US National Cancer Institute (NCI) National Clinical Trials Network cooperative groups. Pfizer and Ipsen provided drug supply; neither company had any role in the conduct of the trials or analyses of the data, or in this manuscript. SOFTand TEXT receive financial support for trial conduct and/or long-term follow-up from Pfizer, Ipsen, TerSera, National Health & Medical Research Council Australia grant numbers 351161, 510788 and 1105058, NCI, Breast Cancer Research Foundation and IBCSG.